verapamil has been researched along with Exocrine Pancreatic Insufficiency in 1 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Exocrine Pancreatic Insufficiency: A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS.
Excerpt | Relevance | Reference |
---|---|---|
"The 2 patients with recurrences are now successfully treated with a calcium channel blocker, an approach, to our knowledge, never before reported for adult-onset nesidioblastosis." | 2.41 | Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma. ( Costa, EA; Kaplan, EL; Koka, MR; Straus II, FH; Sugg, SL; Witteles, RM, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Witteles, RM | 1 |
Straus II, FH | 1 |
Sugg, SL | 1 |
Koka, MR | 1 |
Costa, EA | 1 |
Kaplan, EL | 1 |
1 review available for verapamil and Exocrine Pancreatic Insufficiency
Article | Year |
---|---|
Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma.
Topics: Adult; Age of Onset; Calcium Channel Blockers; Combined Modality Therapy; Diabetes Mellitus, Type 1; | 2001 |